GLP-1R reporter cell line advances diabetes and obesity research

AMSBIO has introduced a new Glucagon-Like Peptide 1 Receptor (GLP-1R) reporter cell line, designed to advance research in diabetes and obesity. GLP-1R plays a crucial role in blood sugar regulation by enhancing glucose-stimulated insulin secretion, making it a key target for type 2 diabetes treatments. The regulation of the GLP-1R signalling pathway has led to the development of several FDA-approved GLP-1 agonists. Additionally, GLP-1R agonists aid in weight management, reduce cardiovascular disease risk, and protect pancreatic beta cells.

The new GLP-1R/CRE Luciferase Reporter HEK293 cell line measures luciferase activity to monitor GLP-1R activation in cells. This cell line is ideal for cell-based binding assays and screening human GLP-1R agonists. Its functionality has been validated in dose-response assays with both peptide and small molecule agonists.

AMSBIO has also launched gastric inhibitory polypeptide receptor (GIPR) and glucagon receptor (GCGR) reporter cell lines to complement the GLP-1R cell line. These receptors are vital for blood sugar regulation, and dual agonists targeting GIPR/GCGR and GLP-1R show promise for type 2 diabetes and obesity treatments. Together, these cell lines offer a robust platform for screening combination therapies by measuring the activity of co-stimulatory targets in response to agonists.

To assist investigations into muscle loss caused by GLP-1R agonists, AMSBIO also offers a range of skeletal muscle research products.

More information online